Single Blog

Small Molecule Drugs
Structural illustration of KRAS protein highlighting the switch II pocket targeted by modern KRASG12C inhibitors in cancer therapy

Why KRAS Was Long Considered “Undruggable” and How New KRAS Inhibitors Are Changing Cancer Therapy

Why KRAS Became the Iconic “Undruggable” Target

For decades, KRAS has been one of the most notorious oncogenes in cancer biology. Mutations in KRAS drive tumor growth in pancreatic, colorectal, and lung cancers, yet attempts to inhibit it with small molecules repeatedly failed. The protein’s surface is smooth and lacks deep, druggable pockets, and its picomolar affinity for GTP/GDP made competitive inhibition seem impossible.

This combination of structural flatness and high-affinity nucleotide binding earned KRAS the label “undruggable.” Medicinal chemists, structural biologists, and oncologists spent years trying—and failing—to design molecules that could selectively and safely shut KRAS down.

How KRASG12C Inhibitors Opened the Door

The first real breakthrough came with covalent KRASG12C inhibitors such as sotorasib and adagrasib. These drugs exploit a unique cysteine residue created by the G12C mutation and bind irreversibly to a previously hidden pocket (the “switch II pocket”) in the inactive GDP-bound form of KRASG12C.
By locking KRASG12C in its inactive state, they suppress downstream signaling through the MAPK pathway and slow tumor growth in a subset of non-small cell lung cancer patients.https://doi.org/10.1056/NEJMoa1917239

Yet, KRASG12C mutations represent only a fraction of KRAS-driven cancers, and resistance emerges quickly. The next generation of small molecule KRAS inhibitors aims to move beyond this narrow slice of patients.

Beyond G12C: Targeting Other KRAS Mutations

KRASG12D and KRASG12V: The Big Unmet Need

KRASG12D and KRASG12V are far more common than G12C, especially in pancreatic and colorectal cancers. However, these variants lack the reactive cysteine that made covalent G12C inhibition possible.

New small molecules are being engineered to recognize subtle conformational differences and transient pockets that appear during the KRAS nucleotide cycle. Some candidates seek to:

  • Preferentially bind the inactive (GDP-bound) form of KRAS, similar to G12C inhibitors but without covalent attachment.
  • Stabilize inactive conformations by engaging allosteric sites near the switch regions.
  • Exploit mutation-specific microenvironments that alter local dynamics and pocket accessibility.

Early preclinical data suggest that non-covalent inhibitors can selectively target KRASG12D and suppress signaling, but translating this into durable clinical benefit remains a major challenge.https://doi.org/10.1038/s41586-022-04529-z

New Strategies: From Pan-KRAS Blockade to Combination Therapies

Pan-KRAS Inhibitors and “State-Selective” Targeting

One emerging concept is pan-KRAS inhibition—designing molecules that bind multiple mutant forms (and sometimes wild-type) by targeting shared conformational states rather than specific residues. Instead of focusing on the mutation site, these drugs aim at:

  • Switch I/II interface pockets that regulate effector binding.
  • Allosteric grooves that control nucleotide exchange.
  • Transient cryptic pockets that appear only in certain conformations.

“State-selective” inhibitors, for example, preferentially bind the inactive GDP state or block SOS1-mediated nucleotide exchange, indirectly shutting down KRAS signaling.https://doi.org/10.1038/s41586-020-2772-0

Combining KRAS Inhibitors with Pathway Blockers

Resistance to KRAS inhibition often arises through pathway reactivation—tumors upregulate RTKs, activate parallel pathways, or acquire secondary mutations. To counter this, trials are exploring rational combinations, including:

  • KRAS inhibitor + SHP2 inhibitor to block upstream RTK signaling and prevent KRAS reactivation.
  • KRAS inhibitor + MEK or ERK inhibitor to deepen MAPK pathway suppression.
  • KRAS inhibitor + immune checkpoint inhibitor to leverage immunogenic changes in the tumor microenvironment.

These combinations aim to transform modest single-agent responses into more durable remissions.

Can We Finally Declare KRAS “Druggable”?

The field has moved from “undruggable” to “difficult but tractable.” Covalent G12C inhibitors proved that small molecules can directly bind KRAS in patients and produce meaningful responses. The next wave—non-covalent, pan-mutant, and state-selective inhibitors—seeks to extend this success to the broader KRAS-mutant population.

Key questions remain: Can we achieve deep, durable pathway suppression without intolerable toxicity? Will resistance always outpace our chemistry? And can rational combinations convert partial responses into long-term control?

What is clear is that KRAS is no longer a distant, theoretical target. It is now an active, rapidly evolving arena for small molecule innovation—and the next generation of KRAS inhibitors may finally turn one of oncology’s toughest adversaries into a manageable, druggable node in cancer therapy.

Selected References